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Abstract 
Background: Brain edema is a significant challenge facing clinicians managing severe traumatic brain injury (TBI) in 
the acute period. If edema reaches a critical point, it leads to runaway intracranial hypertension that, in turn, leads to 
severe morbidity or death if left untreated. Clinical data on the efficacy of standard interventions is mixed. The goal 
of this study was to validate a novel therapeutic strategy for reducing post-traumatic brain edema in a mouse model. 
Prior in vitro work reported that the brain swells due to coupled electrostatic and osmotic forces generated by large, 
negatively charged, immobile molecules in the matrix that comprises brain tissue. Chondroitinase ABC (ChABC) 
digests chondroitin sulfate proteoglycan, a molecule that contributes to this negative charge. Therefore, we adminis-
tered ChABC by intracerebroventricular (ICV) injection after controlled cortical impact TBI in the mouse and measured 
associated changes in edema.
Results: Almost half of the edema induced by injury was eliminated by ChABC treatment.
Conclusions: ICV administration of ChABC may be a novel and effective method of treating post-traumatic brain 
edema in the acute period.
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Background
Traumatic brain injury (TBI) is responsible for 36  % 
of deaths among children 1–14  years old and is a lead-
ing cause of death among those in the 15–45  year age-
bracket [1]. It is also responsible for 40  % of combat 
deaths among US military personnel [2]. Brain edema 
within the rigid confines of the skull elevates intracra-
nial pressure (ICP) [3] and, in severe cases, leads to her-
niation of the brain tissue which is frequently fatal [4]. 
Elevated ICP occludes blood vessels causing cerebral 
hypoperfusion, and elevated ICP correlates with poor 
outcome [5]. Unfortunately, currently available tools for 
managing post-traumatic edema suffer from serious limi-
tations. Draining cerebrospinal fluid (CSF) compensates 
for the increased volume of the brain to a point, but the 
volume of CSF available to drain is often less than that 
needed to accommodate severe edema. Hyper-osmotic 
solutions of saline or mannitol can be administered sys-
temically to draw water out of the brain. However, the 
subsequent reduction of ICP is sometimes short-lived 
and may be followed by rebound of ICP to or above the 
pre-treatment level [6]. Some surgeons perform decom-
pressive craniectomies to relieve ICP in refractory cases. 
Clinical trial data on the effectiveness of this interven-
tion is currently lacking [7], and the risk of infection and 
injury to the brain at the edge of the craniectomy are 
important drawbacks [8]. In summary, there is an urgent 
clinical need for new therapeutic strategies to address 
post-traumatic brain edema.
Coupled electrostatic and osmotic forces cause edema 
in injured brain tissue [9, 10]. In brain, as in many biolog-
ical tissues, an ionic solution permeates a porous, solid 
matrix containing large, immobile, negatively charged 
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molecules. The negatively charged molecules that are 
bound to the solid phase of the tissue electrostatically 
attract ions from the intracellular and extracellular fluid, 
thereby increasing the ion-concentration within the tis-
sue as compared to the fluid surrounding the tissue and 
creating an osmotic gradient that draws in water. A field 
of biomechanics known as triphasic theory quantitatively 
describes these coupled electrostatic and osmotic forces 
[11]. Previously we have shown that biologically inert (i.e. 
dead) brain tissue swells in a manner that conforms to 
the highly non-linear predictions of triphasic theory, vali-
dating this model [9]. The healthy brain is highly meta-
bolic, and much of the energy generated by metabolism 
is used to regulate ion concentrations in the tissue [12]. 
Therefore, healthy brain tissue is normally far from ther-
modynamic equilibrium, and its volume is less than that 
predicted by the physical laws of triphasic theory. How-
ever, when the brain is injured and ion flux out of cells 
is compromised, either because of reduced metabolism 
or damaged cell membranes, the damaged tissue moves 
toward thermodynamic equilibrium, i.e. it swells.
This physical model of post-traumatic brain edema 
motivated our therapeutic strategy. One of the most 
abundant of the large, immobile, negatively charged mol-
ecules in the tissue that drive edema is chondroitin sulfate 
proteoglycan (CSPG) [9]. CSPG also has a very low pKa 
(between 3 and 4 depending on the ionic strength of the 
solution [13]), meaning that it is very negatively charged 
at physiological pH. Chondroitinase ABC (ChABC) is 
an enzyme that degrades CSPG, thereby mobilizing its 
negative charge. This allows it to diffuse out of the solid 
matrix and reduce the osmotic potential to draw in water. 
ChABC has been studied at length in the central nerv-
ous system as a means of breaking down glial scars that 
inhibit axon regeneration [14–16] and is generally well-
tolerated in rodents. For example, there was no change 
in visual field or acuity after ChABC was injected into 
the visual cortex in mice [17]. In addition to being gener-
ated in response to injury during scar formation, CSPGs 
exist throughout the brain in the absence of injury. They 
are abundant in perineuronal nets, extracellular struc-
tures that surround neurons and inhibit synaptic plastic-
ity [18]. Previous in vitro work by our group showed that 
ChABC reduced edema in dead and injured brain tissue 
[10]. Therefore, we hypothesized that administration of 
ChABC would reduce post-traumatic brain edema in the 
mouse model of controlled cortical impact (CCI) TBI.
Methods
All animal procedures were conducted according to the 
guidelines set forth in the Guide for the Care and Use of 
Laboratory Animals [19] and were approved by the Insti-
tutional Animal Care and Use Committee at Columbia 
University. A total of 40 mice were used in this study. Ten 
week old male C57/BL6 mice were anesthetized with iso-
flurane and placed in a stereotactic frame. The skull was 
exposed, and a 5  mm diameter craniotomy was drilled 
to the left of the sagittal suture between lambda and 
bregma. An Impact One device (Leica Biosystems, Buf-
falo Grove, IL) was used to propel a 3 mm diameter, flat-
ended, cylindrical indenter into the brain to a depth of 
1.3 mm at a speed of 5 ms−1 with a dwell time of 300 ms 
at a 10° angle to the vertical. In uninjured controls, the 
skull was exposed but not opened to eliminate the risk of 
damage during the craniotomy. The treatment consisted 
of 10 μl of a filter-sterilized 50 U/ml solution of ChABC 
(Sigma Aldrich, St. Louis, MO) dissolved in PBS. Within 
5 min after injury, ChABC or vehicle was administered to 
the right lateral ventricle using a Hamilton syringe with 
a 26G needle inserted to a depth of 3 mm at a location 
1 mm to the right and 0.3 mm anterior to bregma [20]. In 
preliminary experiments, a green tracer dye was injected 
to verify that agents injected at this point permeated the 
ventricular network. A group of uninjured animals was 
also injected to measure the effect of ChABC on water 
content in healthy brain tissue. To evaluate the effect of 
treatment 5 min after injury on edema 24 h after injury, 
animals were euthanized by cervical dislocation under 
deep anesthesia at the 24  h time point and the brains 
were immediately removed. A 4  mm thick coronal slice 
of brain tissue encompassing the lesion site was cut from 
the mid-brain and split into two hemispheres (ipsilateral 
and contralateral to the injury). Each hemisphere was 
weighed, dried at 95° C for 72 h, and then weighed again 
to determine the water fraction.
Results and discussion
There was no statistically significant effect of ChABC 
treatment on water fraction in uninjured animals 
(n =  10, Fig.  1a). In injured animals, the water fraction 
was 1.13  % higher in the ipsilateral hemisphere than in 
the contralateral hemisphere, indicating edema due to 
injury (Fig. 1b). Previously reported values for edema in 
this injury model range from 1 to 3 % [21–24]. These val-
ues are small because controlled cortical impact induces 
a focal lesion so only a small domain in the tissue sam-
ple tested has increased water content. Smaller tissue 
samples excised at the lesion site in a controlled cortical 
impact model showed a greater change in water content 
[25]. Treatment significantly reduced ipsilateral water 
fraction by 0.54 % (p < 0.05, ANOVA followed by Bonfer-
roni post hoc test, n = 10, Fig. 1b), indicating that almost 
half of the edema induced by trauma was eliminated. The 
fact that the treatment affected water fraction more in 
injured animals than in uninjured animals suggests that 
it acts selectively on injured tissue. This selectivity may 
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be an important advantage in light of the global delivery 
modality tested here.
There are several clinically established treatments for 
brain edema, and others have been proposed. However, 
none of the established or proposed treatments employs 
the same mechanism of action as ChABC treatment, 
suggesting that ChABC treatment would offer addi-
tional benefits when applied in combination with other 
established or proposed treatments for brain edema. 
Established treatments such as elevation of the head, 
CSF drainage, hyperosmotic therapy and decompres-
sive craniectomy do not alter the fixed charge density, 
which is the target of ChABC treatment. Inhibition of 
aquaporin 4 (AQP4) has been proposed as a treatment 
for brain edema [26]. Aquaporin 4 is a water channel in 
the blood brain barrier (BBB). Genetic deletion of AQP4 
reduced brain swelling after stroke by about a third [26], 
prompting an ongoing search for a small molecule that 
inhibits AQP4. Such a treatment would complement 
rather than replace ChABC treatment because AQP4 
inhibition increases the resistance to water flow across 
the BBB while ChABC treatment reduces the osmotic 
pressure driving that flow. Another recently proposed 
treatment for brain edema employs an osmotic trans-
port device that is placed on the exposed cortex to draw 
water out of the tissue [21]. Chondroitinase ABC treat-
ment would again complement this therapy because it 
would reduce the competing osmotic pressure that tends 
to hold water in the tissue.
The ICV route of administration was selected because 
it offered a combination of efficacy and clinical con-
venience. Intraparenchymal injection of ChABC in 
mice affects only a small region of the brain around the 
injection site and therefore may be inappropriate for 
treating more widespread edema [17]. Intravenous deliv-
ery is impractical because ChABC is too large to cross 
an intact BBB. A ventricular shunt is typically placed in 
patients with severe TBI to drain CSF as a first-line ther-
apy to combat edema and control ICP [27]. This shunt 
can be used to administer therapeutic agents. Idursulfase, 
an enzyme with a similar substrate, successfully perme-
ates brain tissue when administered to primates via ICV 
injection [28], suggesting that ICV delivery of ChABC 
would be similarly successful. In our study, an effica-
cious dose of ChABC was delivered via the ventricular 
space remote from the site of injury, suggesting that this 
strategy can be used to address global edema using ven-
tricular shunts that are routinely placed as part of first-
line therapy. However, the murine brain is much smaller 
than the human brain and the lissencephalic anatomy 
may allow easier access to the swollen cortex than the 
gyrencephalic anatomy of the human brain. Therefore, 
ICV delivery may be less effective in the human. Another 
important limitation of the current study is that treat-
ment was administered within 5  min post-injury. The 
time to reach, stabilize and transport a severely brain 
injured patient creates an unavoidable delay of several 
hours between injury and treatment. Further investi-
gation is necessary to fully understand how the timing 
of the therapeutic dose influences the time course of 
post-injury edema. Unfortunately, a thorough inves-
tigation of time course may require a different animal 
model. In humans, the brain is massive and is confined 
within the rigid cranial vault. This confinement creates 
positive feedback between edema, intracranial pressure 
and ischemia. This phenomenon is known as runaway 
Fig. 1 The effect of ChABC treatment on brain water content. a Water fraction was not significantly affected by ChABC treatment in uninjured 
animals. b ChABC treatment reduced water fraction in the brain hemisphere ipsilateral to the injury in injured animals (*, p < 0.05, ANOVA followed 
by Bonferroni post hoc test, mean ± standard error, n = 10)
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intracranial hypertension and it strongly influences the 
course of post-traumatic edema in the days following a 
severe TBI. In mice, the brain is smaller and the skull is 
more flexible so this feedback effect is weaker. Therefore, 
the model presented here is appropriate to the study of 
post-traumatic edema but not for the study of subse-
quent runaway intracranial hypertension. Nevertheless, 
these preliminary results show that chondroitinase ABC 
can mitigate post-traumatic edema in vivo and this indi-
cates that it may mitigate runaway intracranial hyperten-
sion in humans.
Conclusions
This study demonstrated that ICV administration of 
ChABC eliminated almost half of the edema induced by 
CCI TBI in mice. Chondroitinase ABC has been tested 
extensively in the mouse brain for other purposes (i.e. not 
for treating edema) without evidence of toxicity [14–17]. 
Therefore, we believe that ChABC may be a promising 
new therapy for addressing post-traumatic brain edema.
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